Back icon Back
Freenome

Freenome

Company

By Sriparna Roy
Feb 15 (Reuters) – Blood test developer Freenome said on Thursday it has raised $254 million in a new funding round led by Swiss drugmaker Roche, to develop tests that can potentially detect multiple early-stage cancers. The company did not disclose the valuation at which the funds were raised.

https://www.reuters.com/business/healthcare-pharmaceuticals/cancer-test-firm-freenome-raises-254-mln-fresh-funding-2024-02-15/

Date

Feb 15, 2024

Category

healthcare

Lead investor

Country Icon Roche Venture Fund

Stage

Series E

Size

$254M

Explore similar Investments to Freenome

Company
Size
Date
Lead Investor
Press
Adopt AI

Adopt AI

Company
$6M
May 13, 2025
Investor Elevation Capital
Source
Pendulum

Pendulum

Company
$22M
Feb 6, 2025
Investor Lowercarbon Capital
Source
Moment

Moment

Company
$36M
Jul 9, 2025
Investor Index Ventures
Source
Riverside

Riverside

Company
$30M
Dec 9, 2024
Investor Zeev Ventures
Source
LlamaIndex

LlamaIndex

Company
$19M
Mar 4, 2025
Investor Norwest Venture Partners
Source
Fern

Fern

Company
$9M
Apr 10, 2025
Investor Bessemer Venture Partners
Source
Sana

Sana

Company
$55M
Oct 30, 2024
Investor NEA
Source
Port IO

Port IO

Company
$35M
Oct 15, 2024
Investor Accel
Source
Lightsource

Lightsource

Company
$33M
Apr 1, 2025
Investor Bain Capital Ventures
Source
TwelveLabs

TwelveLabs

Company
$30M
Dec 12, 2024
Investor HubSpot Ventures
Source
Plenful

Plenful

Company
$50M
Apr 30, 2025
Investor Notable Capital
Source
Tessl

Tessl

Company
$125M
Nov 14, 2024
Investor Index Ventures
Source

Startups, venture funds
& everything in between.

Explore verified companies, top VCs, and practical guides built to help you raise, invest, and grow faster.
Made by Omnius. For builders, by builders.
Venture Funds Startups Investments Events Programs Case Studies Interviews & Lectures Reports & Publications